N@N

Perceptive Informatics Improves Clinical Trial Management With New Release Of IMPACT CTMS Solution

^{Published on 2013-04-03 04:00:55 - Market Wire}
 

Perceptive Informatics Improves Clinical Trial Management With New Release Of IMPACT CTMS Solution -- BOSTON, April 3, 2013 /PRNewswire/ --

BOSTON, April 3, 2013 /PRNewswire/ -- [ Perceptive Informatics ], a leading [ eClinical ] solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: [ PRXL ]), today released an enhanced version of its comprehensive IMPACT® [ clinical trial management system ] (CTMS). Notable features include improved data entry as well as site management and monitoring capabilities. The system is designed for pharmaceutical and biotechnology companies of all sizes, and has more than 26,000 users in studies of up to tens of thousands of subjects and millions of visits.

According to market research firm MarketsandMarkets, the CTMS software industry is expected to jump from $567.2 million in 2010 to $1.3 billion by 2016.[1]  Perceptive Informatics' [ CTMS ] solution provides a user-friendly infrastructure that enables clinicians to manage trials of varying complexity.

"Many top global pharmaceutical companies and CROs rely on the IMPACT CTMS solution to plan, administer and track every aspect of their clinical trials," said Nick Richards , Vice President, Product Management, Perceptive Informatics. "As clients face further globalization of clinical trials and require site management and monitoring of increasingly complex studies, they need technology that keeps pace. Perceptive's enhanced system represents a significant leap forward in flexibility and usability, enabling clients to improve the speed and effectiveness of their clinical development programs."

Perceptive's enhanced version is a customizable system which allows managers the flexibility to define which information is most important to their clinical trial and configure it accordingly. Highlights include:

• Configurability by Clinical Trial Type– Customers can define their own clinical trial types – from single-site investigator-initiated studies to large multi-country studies – enabling them to select the critical screens and fields that each requires. This simplifies and streamlines clinical trial management and ensures that users see exactly what they need.
• Assistance for Field Monitors– The IMPACT® MySites™ Module, which supports online and offline monitoring activities and the collection of associated management data, now enables contract research associates to record and manage contacts for the sites they monitor, allowing them to have a more comprehensive view of site activity.
• Improved Data Mining Capabilities– The IMPACT® Investigator Module's advanced search feature enables users to select physician names based on their location, specialty, therapeutic interests, responses to qualification questionnaires and investigator performance metrics in order to speed the finalization of candidate study sites and the recruitment of optimal investigators for a trial.

Perceptive Informatics' IMPACT CTMS solution is used to plan, track and report on clinical trials and is available as a hosted, software-as-a-service ([ SaaS ]) application. It is an integral part of the [ Perceptive MyTrials^TM ] platform, which provides an application framework to converge its integrated suite of clinical trial software. For more information visit: [ http://www.perceptive.com/ctms/impact ]

[1] MarketsandMarkets, "Clinical Trial Management Systems (CTMS) Market: Global Trends, Opportunities, Challenge and Forecasts (2011 - 2016)," January 2012.

About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics^® eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, [ Medical Imaging ], Clinical Trial Management Systems (CTMS), [ Electronic Data Capture ] (EDC), Electronic Patient-Reported Outcomes (ePRO), and Regulatory Information Management solutions.  The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit [ www.perceptive.com ].

About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 73 locations throughout 51 countries around the world, and has approximately 14,000 employees. For more information about PAREXEL International visit [ www.PAREXEL.com ].

This release contains "forward-looking" statements regarding future results and events.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2012 as filed with the SEC on February 1, 2013, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL, Perceptive Informatics, Perceptive, ClinPhone, DataLabs, IMPACT, and Liquent are registered trademarks of PAREXEL International Corporation and its subsidiaries.  All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.

Contacts:

Diana Martin , Vice President Corporate Communications
PAREXEL International
Tel: +1 781 434-5516
Email: [ Diana.Martin@PAREXEL.com ]

Kim Leadley
PAN Communications
Tel: +1 617-502-4300
Email: [ PAREXEL@pancomm.com ]

SOURCE Perceptive Informatics